Atara Biotherapeutics (ATRA) Free Cash Flow (2013 - 2026)
Atara Biotherapeutics (ATRA) posted Free Cash Flow of -$3.1 million for Q1 2026, up 46.06% on a QoQ basis from -$5.7 million in Q4 2025, and up 89.08% year-over-year from -$1.6 million in Q1 2025.
Atara Biotherapeutics (ATRA) Free Cash Flow (2013 - 2026) Analysis & Trends
Atara Biotherapeutics' Free Cash Flow history runs 14 years deep, the most recent figure standing at -$3.1 million for Q1 2026.
- Quarterly Free Cash Flow rose 89.08% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.9 million (up 61.66% YoY) and the FY2025 annual result came in at -$50.9 million, up 26.13% from the prior year.
- Free Cash Flow was -$3.1 million for Q1 2026 at Atara Biotherapeutics, up from -$5.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$3.1 million in Q1 2026 and bottomed at -$87.1 million in Q1 2022.
- A 5-year average of -$34.4 million and a median of -$29.6 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow surged 92.27% — and 2025, when it plunged 145.35%.
- Atara Biotherapeutics' Free Cash Flow stood at -$56.9 million in 2022, then grew by 15.33% to -$48.2 million in 2023, then soared by 49.03% to -$24.6 million in 2024, then jumped by 76.8% to -$5.7 million in 2025, then soared by 46.06% to -$3.1 million in 2026.
- Business Quant data shows ATRA's Free Cash Flow at -$3.1 million in Q1 2026, -$5.7 million in Q4 2025, and -$9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.95 Mn |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | -3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.07 Mn |
| Mar 31, 2026 | -3.07 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Sep 30, 2025 | -9.79 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Jun 30, 2025 | -7.32 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Mar 31, 2025 | -28.14 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Dec 31, 2024 | -24.56 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Sep 30, 2024 | -3.99 Mn |
| Jun 30, 2024 | -10.80 Mn |
| Jun 30, 2024 | -10.80 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Mar 31, 2024 | -29.61 Mn |
| Dec 31, 2023 | -48.18 Mn |
| Dec 31, 2023 | -48.18 Mn |